These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 34181364)

  • 1. Treating Attention-Deficit/Hyperactivity Disorder in Severe Intellectual Disability with Lisdexamfetamine: A Case Report.
    Araújo A; Madeira N; Ventura F; Morais S; Coroa M; Macedo A; Areias G; Borges J
    J Clin Psychopharmacol; 2021 Jul-Aug 01; 41(4):490-492. PubMed ID: 34181364
    [No Abstract]   [Full Text] [Related]  

  • 2. Review of lisdexamfetamine dimesylate in children and adolescents with attention deficit/hyperactivity disorder.
    Najib J; Didenko E; Meleshkina D; Yusupov K; Maw K; Ramnarain J; Tabassum M
    Curr Med Res Opin; 2020 Oct; 36(10):1717-1735. PubMed ID: 32845786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional outcomes from a head-to-head, randomized, double-blind trial of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder and an inadequate response to methylphenidate.
    Nagy P; Häge A; Coghill DR; Caballero B; Adeyi B; Anderson CS; Sikirica V; Cardo E
    Eur Child Adolesc Psychiatry; 2016 Feb; 25(2):141-9. PubMed ID: 25999292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Lisdexamfetamine dimesylate: a Treatment Option for Children and Adolescents with Attention Deficit/Hyperactivity Disorder in Germany and Across Europe].
    Häge A; Banaschewski T; Dittmann RW
    Fortschr Neurol Psychiatr; 2015 Dec; 83(12):676-85. PubMed ID: 26714249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Growth and Puberty in a 2-Year Open-Label Study of Lisdexamfetamine Dimesylate in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.
    Banaschewski T; Johnson M; Nagy P; Otero IH; Soutullo CA; Yan B; Zuddas A; Coghill DR
    CNS Drugs; 2018 May; 32(5):455-467. PubMed ID: 29790103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expanded access to publicly subsidised lisdexamfetamine treatment for adults with attention-deficit/hyperactivity disorder: An interrupted time-series analysis.
    Bruno C; Zoega H; Gillies MB; Havard A; Coghill D; Pearson SA; Brett J
    Aust N Z J Psychiatry; 2023 Jul; 57(7):1073-1076. PubMed ID: 37122132
    [No Abstract]   [Full Text] [Related]  

  • 7. A new amphetamine oral suspension (Adzenys ER) for ADHD.
    Med Lett Drugs Ther; 2018 Jun; 60(1549):e106-e108. PubMed ID: 29913476
    [No Abstract]   [Full Text] [Related]  

  • 8. Patterns of Lisdexamfetamine Dimesylate Use in Children, Adolescents, and Adults with Attention-Deficit/Hyperactivity Disorder in Europe.
    Siffel C; Page M; Maxwell T; Thun B; Kolb N; Rosenlund M; von Bredow D; Keja J
    J Child Adolesc Psychopharmacol; 2020 Sep; 30(7):439-447. PubMed ID: 32315539
    [No Abstract]   [Full Text] [Related]  

  • 9. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
    CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Updated 2018 NICE guideline on pharmacological treatments for people with ADHD: a critical look.
    Faltinsen E; Zwi M; Castells X; Gluud C; Simonsen E; Storebø OJ
    BMJ Evid Based Med; 2019 Jun; 24(3):99-102. PubMed ID: 30530806
    [No Abstract]   [Full Text] [Related]  

  • 11. Parent-Reported Improvements in Family Functioning in a Randomized Controlled Trial of Lisdexamfetamine for Treatment of Parental Attention-Deficit/Hyperactivity Disorder.
    Babinski DE; Waxmonsky JG; Waschbusch DA; Humphery H; Pelham WE
    J Child Adolesc Psychopharmacol; 2017 Apr; 27(3):250-257. PubMed ID: 27991835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Psychostimulants: An Overview].
    Fukumoto S; Imanari E; Tomari S; Higashi T; Kosaka H
    Brain Nerve; 2023 May; 75(5):599-604. PubMed ID: 37194538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Catatonia in a 12-Year-Old Child.
    Shrivastava SVK; Poulsen R; Mavrides N; Coffey BJ
    J Child Adolesc Psychopharmacol; 2021 Mar; 31(2):144-146. PubMed ID: 33734906
    [No Abstract]   [Full Text] [Related]  

  • 14. [New-onset trichotillomania during treatment with stimulant drugs. About two pediatric clinical cases].
    Fernández Manso B; Villora Morcillo N; Taboas Pereira MA; Elipe Maldonado C
    Arch Argent Pediatr; 2020 Feb; 118(1):e61-e62. PubMed ID: 31984712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lisdexamfetamine Dimesylate: A Review in Paediatric ADHD.
    Frampton JE
    Drugs; 2018 Jul; 78(10):1025-1036. PubMed ID: 29923015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Attention-deficit/hyperactivity disorder: the road traveled and the road ahead.
    Jun A
    Am J Health Syst Pharm; 2009 Nov; 66(22):2003. PubMed ID: 19890082
    [No Abstract]   [Full Text] [Related]  

  • 17. Lisdexamfetamine in the treatment of attention-deficit/hyperactivity disorder in adults.
    Rostain AL
    Curr Psychiatry Rep; 2009 Oct; 11(5):341-2. PubMed ID: 19785973
    [No Abstract]   [Full Text] [Related]  

  • 18. [Development of cerebral infarcts in a 17-year-old male treated with sertraline and lisdexamfetamine].
    Martinussen M; Debes NM; Christensen C; Leth G; Pagsberg AK; Kruuse C
    Ugeskr Laeger; 2016 Nov; 178(45):. PubMed ID: 27855771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A cost-effectiveness analysis of lisdexamfetamine dimesylate in the treatment of adults with attention-deficit/hyperactivity disorder in the UK.
    Zimovetz EA; Joseph A; Ayyagari R; Mauskopf JA
    Eur J Health Econ; 2018 Jan; 19(1):21-35. PubMed ID: 28093662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantifying the Protective Effects of Stimulants on Functional Outcomes in Attention-Deficit/Hyperactivity Disorder: A Focus on Number Needed to Treat Statistic and Sex Effects.
    Biederman J; DiSalvo M; Fried R; Woodworth KY; Biederman I; Faraone SV
    J Adolesc Health; 2019 Dec; 65(6):784-789. PubMed ID: 31350122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.